Nitiloop is an Israeli medical device startup specializing in the development of innovative solutions for the revascularization of coronary and peripheral chronic total occlusions (CTO). The company operates in the medical technology market, primarily serving interventional cardiologists and healthcare institutions across the U.S., Europe, and Israel. Nitiloop's core product is a device designed to facilitate proximal cap crossing and success with antegrade wiring in complex lesions, significantly improving procedural success rates while minimizing risks such as perforation. The device has undergone rigorous clinical evaluation, including a pivotal FDA approval trial, demonstrating high efficacy and safety. Nitiloop generates revenue through the sale of its medical devices to hospitals and clinics, leveraging its FDA clearance to expand market adoption. The business model focuses on providing a critical tool for both high-volume and low-volume cath lab clinicians, ensuring ease of use without requiring additional training.

Keywords: revascularization, coronary CTO, peripheral CTO, medical device, FDA clearance, interventional cardiology, proximal cap crossing, antegrade wiring, clinical efficacy, healthcare innovation.